for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Psychemedics Corp.

PMD.OQ

Latest Trade

6.80USD

Change

-0.21(-3.00%)

Volume

964

Today's Range

6.78

 - 

7.02

52 Week Range

3.58

 - 

7.81

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
7.01
Open
7.02
Volume
964
3M AVG Volume
0.82
Today's High
7.02
Today's Low
6.78
52 Week High
7.81
52 Week Low
3.58
Shares Out (MIL)
5.54
Market Cap (MIL)
38.26
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Psychemedics Corporation Reports Fourth Quarter And Full Year 2020 Financial Results

Psychemedics Reports Q3 Loss Per Share Of $0.20

Psychemedics Corp - On Sept 3, Co Reduced Base Salaries Of All Of Executive Officers

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Psychemedics Corp.

Psychemedics Corporation (Psychemedics) provides hair testing for drugs of abuse, utilizing a hair analysis method involving digestion of hair, enzyme immunoassay (EIA) technology and confirmation by mass spectrometry to analyze human hair to detect abused substances. The Company operates in drug testing services segment. The Company is in the business of performing drug testing and reporting the results thereof. The Company's drug testing services include training for collection of samples and storage of positive samples for its customers for an agreed-upon fee per unit tested of samples. The Company's primary application of its technology is as a testing service that analyzes hair samples for the presence of certain drugs of abuse. The Company's tests provide information that indicates the approximate amount of drug ingested, as well as historical data, which shows a pattern of individual drug use over a longer period of time.

Industry

Healthcare Facilities

Contact Info

125 Nagog Park Ste 200

ACTON, MA

01720-3451

United States

+1.800.6288073

https://www.psychemedics.com/

Executive Leadership

Raymond C. Kubacki

Chairman of the Board, President, Chief Executive Officer

Charles Doucot

Executive Vice President

Michael I. Schaffer

Vice President - Laboratory Operations

Andrew Limbek

Vice President, Controller

Harry F. Connick

Independent Director

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
1.79
Price To Book (MRQ)
3.06
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
33.02
LT Debt To Equity (MRQ)
27.53
Return on Investment (TTM)
-18.48
Return on Equity (TTM)
-14.98

Latest News

Latest News

BRIEF-Psychemedics Q1 Loss Per Share $0.03

* Q1 REVENUES AND EARNINGS WERE NEGATIVELY IMPACTED BY CORONAVIRUS PANDEMIC Source text for Eikon: Further company coverage:

BRIEF-Psychemedics Test For Cotinine (Metabolite Of Nicotine) Detection Cleared By FDA

* PSYCHEMEDICS TEST FOR COTININE (METABOLITE OF NICOTINE) DETECTION CLEARED BY FDA

BRIEF-Psychemedics Reports Q4 Loss Per Share $0.09

* REVENUE AND EARNINGS WERE AFFECTED BY LOWER SALES VOLUME IN QUARTER Source text for Eikon: Further company coverage:

BRIEF-Psychemedics Corp Q1 Earnings Per Share $0.23

* PSYCHEMEDICS ANNOUNCES 1Q RECORD REVENUES AND DIVIDEND INCREASE OF 20%

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up